Skip to main content
Log in

SSRI treatment decreases prolactin and hyperthermic responses to mCPP

  • RAPID COMMUNICATION
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

We studied the effect of 3 weeks treatment with the selective serotonin re-uptake inhibitor (SSRI), paroxetine (30 mg daily), on the neuroendocrine and hyperthermic responses to the 5-HT2C receptor agonist, m-chlorophenylpiperazine (mCPP) (0.05 mg/kg IV), in seven healthy volunteers. Following paroxetine treatment, both the prolactin and hyperthermic responses to mCPP were significantly attenuated. These data are consistent with experimental animal studies indicating that repeated SSRI treatment leads to a functional desensitisation of 5-HT2C receptors. This effect may be linked to the anxiolytic properties of SSRIs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 2 May 1997/Final version: 30 June 1997

Rights and permissions

Reprints and permissions

About this article

Cite this article

Quested, D., Sargent, P. & Cowen, P. SSRI treatment decreases prolactin and hyperthermic responses to mCPP. Psychopharmacology 133, 305–308 (1997). https://doi.org/10.1007/s002130050406

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002130050406

Navigation